Placebo response in depression

Dialogues in Clinical Neuroscience

Volumn 4, Issue 1, 2002, Pages 105-113

  Sonawalla, Shamsah B ^a   Rosenbaum, Jerrold F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trials; Depression; Placebo; Placebo pattern response; True drug response

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

CLINICAL RESEARCH; DEPRESSION; DOCTOR PATIENT RELATION; HUMAN; MEDICAL ETHICS; NOMENCLATURE; PREDICTION; REVIEW; SOCIAL ASPECT;

EID: 0037656409     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Khan A, Brown WA. The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol. 2001;21:123-125.
2. Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology. 1994;10:265-269.
3. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994;11:33-43.
4. Dago PL, Quitkin FM. Role of the placebo in depressive disorders. CNS Drugs. 1995;4:335-340.
5. Shapiro AK. A historic and heuristic definition of the placebo. Psychiatry. 1964;27:52-58.
6. Straus JL, von Ammon Cavanaugh S. Placebo effects. Issues for clinical practice in psychiatry and medicine. Psychosomatics. 1996;37:315-326.
7. Shapiro AK, Morris LA. The placebo effect in medical and psychological psychotherapies. In: Garfield SL, Bergin AE, eds. Handbook of Psychotherapy and Behavior Change. New York, NY: Wiley; 1978:369-410.
8. Brody H. Placebo effect. In: White L, Tursky B, Schwartz G, eds. Placebo: Theory Research and Mechanisms. New York, NY: Guilford Press; 1985:39-49.
9. Ernst E, Resch KL. Concept of true and perceived placebo effects. BMJ. 1995;311:551-553.
10. Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry. 2000;47:687-688.
11. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344:1594-1602.
12. Chaput de Saintonge DM, Herxheimer A. Harnessing placebo effects in health care. Lancet. 1994;344:995-998.
13. Hahn RA. A sociocultural model of illness and healing. In: White L, Tursky B, Schwattz GE, eds. Placebo Theory Research, and Mechanisms. New York, NY: Guilford Press; 1985:167-195.
14. Ranga RK. Efficient trial designs to reduce placebo requirements. Biol Psychiatry. 2000;47:724-726.
15. Buckalew LW, Ross S, Starr BJ. Nonspecific factors in drug effects: placebo personality. Psycho Rep. 1981;48:3-8.
16. Blackwell B, Bloomfield SS, Buncher CR. Demonstration to medical students of placebo responses and non-drug factors. Lancet. 1972;1:1279-1282.
17. Evans FJ. In: White L, Tursky B, Schwartz G, eds. Placebo: Theory, Research and Mechanisms. New York, NY: Guilford Press; 1985:215-228.
18. Forester BP. The use of placebos in psychiatric research. Int J Psychiatry Med. 1999;29:91-95.
19. Smith TC, Thompson TL. The inherent, powerful, therapeutic value of a good physician-patient relationship. Psychosomatics. 1993;3:166-170.
20. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet. 1978;2:654-657.
21. Sheline YI, Black KJ, Bardgett ME, et al. Platelet binding characteristics distinguish placebo responders from nonresponders in depression. Neuropsychopharmacology. 1995;12:315-322.
22. Mayberg HS, Parikh RM, Morris PL, Robinson RG. Spontaneous remission of post-stroke depression and temporal changes in cortical S2-serotonin receptors. J Neuropsychiatry Clin Neurosci. 1991;3:80-83.
23. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998;55:334-343.
24. Rothschild R, Quitkin FM. Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosomatics. 1992;58:170-177.
25. Sonawalla SB, Renshaw PF, Moore CM, et al. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry. 1999;156:1638-1640.
26. Sonawalla SB, Farabaugh AH, Leslie V, Alpert J, Nierenberg A, Fava M. True drug response versus placebo pattern response to fluoxetine: difference in cognitive factors. J Psychiatr Res. 2002. In press.
27. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992;41:203-214.
28. Bialik RJ, Ravindan AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci. 1995;20:265-270.
29. Stewart JW, Quitkin FM, Liebowitz MR, McGrath PJ, Harrison WM, Klein DF. Efficacy of desipramine in depressed outpatients. Arch Gen Psychiatry. 1983;40:202-207.
30. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs. 2001;15:765-776.
31. Stewart JW, McGrath PJ, Quitkin FM. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Am J Psychiatry. 1992;149:615-619.
32. Brown WA, Khan A. Which depressed patients should receive antidepressants? CNS Drugs. 1994;5:341-347.
33. Klein DF. Identified placebo treatment? Neuropsychopharmacology. 1994;10:271-272.
34. Kahn A, Dager SR, Cohen S, Avery DH, Scherzo B, Dunner DL. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology. 1991;4:125-130.
35. Fairchild CJ, Rush JA, Versavada N, Giles DE, Khatami M. Which depressions respond to placebo? Psychiatry Res. 1986;18:217-226.
36. Leuchter, AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122-129.
37. Klerman GL. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull. 1986;22:25-29.
38. Leber PD. Is there an alternative to the randomized clinical trial? Psychopharmacol Bull. 1991;27:3-8.
39. Leber P. Challenges to the ethicality of clinical research. Psychopharmacol Bull. 1996;32:11-13.
40. Rush JA. The use of placebos in unipolar major depression: the current status. Biol Psychiatry. 2000;47:745-747.
41. Andrews G. Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry. 2001;178:192-194.
42. Quitkin FM. Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry. 1999;156:829-836.
43. Enserlink M. Psychopharmacology: can the placebo be the cure? Science. 1999;284:238-240.
44. Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry. 1999;60(suppl 4):23-31.
45. Faries DM, Heilgenstein J, DeBrota DJ, Potter WZ. The double-blind variable placebo lead-in period: results from two antidepressant studies. Poster presented at the 39th Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, Fla, 1999.
46. Keck PE Jr, Welge JA, McElroy SL, Arnold LM, Strakowski LM. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry. 2000;47:748-755.
47. Kraemer HC. Statistical analysis to settle ethical issues? Arch Gen Psychiatry. 2000;57:327-328.
48. Taubes G. Use of placebo controls in clinical trials disputed. Science. 1995;267:25-26.
49. Cochrane AL. Effectiveness and efficacy: random reflections on health services. Control Clin Trials. 1989;10:428-433.
50. World Medical Assembly. Declaration of Helsinki. Geneva, Switzerland: World Health Organization; 1964.
51. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry. 2000;157:327-337.
52. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the food and drug administration database. Arch Gen Psychiatry. 2000;57:311-317.
53. Miller FG. Placebo-controlled trials in psychiatric research: an ethical perspective. Biol Psychiatry. 2000;47:707-716.
54. Murray JCL, Lopez AD. The Global Burden of Disease in 1990. Final results and their sensitivity to alternative epidemiological perspectives, distant rates, age weights, and disability weights. In: Murray JCL, Lopez AD, eds. The Global Burden of Disease. Cambridge, Mass: Harvard University Press; 1996:247-296.
55. Quitkin FM, Rabkin J, Ross D, Stewart JW. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry. 1984;41:782-786.